High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy

Acta Ophthalmologica Scandinavica

Volumn 80, Issue 3, 2002, Pages 316-321

  Kauppinen Mäkelin, Ritva ^a   Karma, Anni ^a   Leinonen, Eeva ^a   Löyttyniemi, Eliisa ^b   Salonen, Oili ^a   Sane, Timo ^a   Setälä, Kirsi ^a   Viikari, Jorma ^c   Heufelder, Armin ^d   Välimäki, Matti ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bone mineral density; Cell adhesion molecule; Corticosteroid treatment; Cytokines; Exophthalmos; Graves' disease; Ophthalmopathy; Thyroid disease

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPRESSION SURGERY; DIPLOPIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; FEMALE; HUMAN; INFLAMMATION; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOFT TISSUE; THYROID DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; DIPLOPIA; EXOPHTHALMOS; FEMALE; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAOCULAR PRESSURE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OCULOMOTOR MUSCLES; PREDNISOLONE; PULSE THERAPY, DRUG; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0036087232     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0420.2002.800316.x     Document Type: Article

References (17)

1. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
2. Therapeutic controversies. Radiation and Graves' ophthalmopathy
3. Soluble interleukin-1 receptor antagonist serum levels in smokers and non-smokers with Graves' ophthalmopathy undergoing orbital radiotherapy
4. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy
5. Supervoltage radiotherapy for progressive Graves' ophthalmopathy: Results of a twenty-year experience
6. Comparison of the effectiveness and tolerability of intravenous and oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study
7. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach
8. Radiotherapy for Graves' ophthalmopathy: Randomized placebo-controlled study
9. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy
10. Graves' ophthalmopathy: Diagnosis and management
11. Prednisone and cyclocporine in the treatment of severe Graves' ophthalmopathy
12. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy
13. Assessment of disease activity of Graves' ophthalmopathy
14. Corticosteroid induced osteoporosis
15. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor antagonist and soluble IL-1 receptor inhibit IL-1 induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy
16. Pathogenesis of Graves' ophthalmopathy
17. An evidence-based approach to the treatment of Graves' ophthalmopathy